Inspire Medical Systems, Inc., in collaboration with Wells Fargo, recently unveiled the Inspire V, a new medical innovation designed to enhance patient lives through sleep therapy. The Inspire V boasts a range of new features, including a flexible software platform that allows for downloadable features and future updates, sleep sync connectivity for remote programming and software updates, and a state-of-the-art technology that enables the stimulation of multiple targets and sensing modes.
One of the key improvements with the Inspire V is its reduced implant time, with a 20% reduction compared to its predecessor, the Inspire 4. This reduction in implant time is coupled with improved therapy performance, resulting in fewer revisions and promising future innovations.
A significant advancement in the Inspire V is the incorporation of a new accelerometer-based sensing technology. This innovation simplifies the implant procedure by reducing the number of leads implanted in the body. Additionally, this new sensing technology allows for the monitoring of a patient's breathing pattern directly inside the generator, ensuring effective treatment with upper airway stimulation.
The closed-loop system of the Inspire V is designed to deliver stimulation at the right time to target the most vulnerable portion of the breathing cycle, thereby preventing airway collapse. This advanced system utilizes an accelerometer inside the generator to monitor the patient's breathing cycle and deliver stimulation accordingly.
The efficacy of the Inspire V was showcased in various data presentations, including the Inspire V Accelerometer Performance Data presented at SLEEP 2024 and the Inspire V Singapore Data presented at SLEEP 2025. These presentations underscored the device's effectiveness in addressing obstructive sleep apnea (OSA) by delivering stimulation at the optimal times during the breathing cycle.
With the full launch of the Inspire V in May 2025, Inspire Medical Systems, Inc. remains committed to providing cutting-edge technology to both healthcare providers and patients. The focus on patient outcomes and operational excellence, coupled with a dedication to innovation and integrity, underscores the company's commitment to advancing sleep therapy and improving patient lives.
Following these announcements, the company's shares moved -3.1%, and are now trading at a price of $128.61. For the full picture, make sure to review Inspire Medical Systems's 8-K report.
